نتائج البحث - Deborah Keefe

  • يعرض 1 - 13 نتائج من 13
تنقيح النتائج
  1. 1
    Trastuzumab‐associated cardiotoxicity

    Trastuzumab‐associated cardiotoxicity حسب Deborah Keefe

    منشور في 2002
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Aliskiren for Geriatric Lowering of Systolic Hypertension: a randomized controlled trial

    Aliskiren for Geriatric Lowering of Systolic Hypertension: a randomized controlled trial حسب Daniel Duprez, Mark Munger, Jaco Botha, Deborah Keefe, Alan N. Charney

    منشور في 2009
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Aliskiren, a Novel Oral Renin Inhibitor, Provides Dose-Dependent Efficacy and Placebo-Like Tolerability in Japanese Patients with Hypertension

    Aliskiren, a Novel Oral Renin Inhibitor, Provides Dose-Dependent Efficacy and Placebo-Like Tolerability in Japanese Patients with Hypertension حسب Toshio Kushiro, Hiroshige Itakura, Yoshihisa Abo, Hiromi Gotou, Shinji Terao, Deborah Keefe

    منشور في 2006
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Direct Renin Inhibition With Aliskiren in Obese Patients With Arterial Hypertension

    Direct Renin Inhibition With Aliskiren in Obese Patients With Arterial Hypertension حسب Jens Jordan, Stefan Engeli, Sam W. Boye, Stéphanie Le Breton, Deborah Keefe

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation.

    Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation. حسب Janice B. Schwartz, Deborah Keefe, Robert E. Kates, E Kirsten, D C Harrison

    منشور في 1982
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Antihypertensive Efficacy of the Oral Direct Renin Inhibitor Aliskiren as Add‐On Therapy in Patients Not Responding to Amlodipine Monotherapy

    Antihypertensive Efficacy of the Oral Direct Renin Inhibitor Aliskiren as Add‐On Therapy in Patients Not Responding to Amlodipine Monotherapy حسب Waymon Drummond, Mark Munger, Mohammed Rafique, Mojdeh Maboudian, Md Mahmudul Hasan Khan, Deborah Keefe

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Effects of the dual sodium–glucose linked transporter inhibitor, licogliflozin <i>vs</i> placebo or empagliflozin in patients with type 2 diabetes and heart failure

    Effects of the dual sodium–glucose linked transporter inhibitor, licogliflozin <i>vs</i> placebo or empagliflozin in patients with type 2 diabetes and heart failure حسب Rudolf A. de Boer, Julio Núñez, Plamen Kozlovski, Yi Wang, Pieter Proot, Deborah Keefe

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Safety and Tolerability of the Direct Renin Inhibitor Aliskiren: A Pooled Analysis of Clinical Experience in More Than 12,000 Patients With Hypertension

    Safety and Tolerability of the Direct Renin Inhibitor Aliskiren: A Pooled Analysis of Clinical Experience in More Than 12,000 Patients With Hypertension حسب William B. White, Robert S. Bresalier, Allen P. Kaplan, Biff F. Palmer, Robert H. Riddell, Anastasia Lesogor, William Chang, Deborah Keefe

    منشور في 2010
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Efficacy and Safety of Fasudil in Patients With Stable Angina

    Efficacy and Safety of Fasudil in Patients With Stable Angina حسب Ralph Vicari, Bernard Chaitman, Deborah Keefe, William Smith, Steven G. Chrysant, Melvin J. Tonkon, Neville Bittar, Robert Weiss, Hugo Morales-Ballejo, Udho Thadani

    منشور في 2005
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial

    Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind rand... حسب Christine Bodemer, Andrzej Kaszuba, Külli Kingo, Athanasios Tsianakas, Akimichi Morita, Enrique Rivas, P. Papanastasiou, Deborah Keefe, Manmath Patekar, Pascal Charef, L. Zhang, Susan Cafoncelli, C. Papavassilis

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*

    Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized contro... حسب Matthias Augustin, Kristian Reich, Paul S. Yamauchi, Andreas Pinter, Jerry Bagel, Swapnil Dahale, R. You, Gerard Bruin, Jimena Djimopoulos, Bertrand Paguet, Pascal Charef, Manmath Patekar, Deborah Keefe

    منشور في 2022
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study

    Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study حسب Miguel R. Abboud, Rodolfo Delfini Cançado, Mariane de Montalembert, Wally R. Smith, Hala Rimawi, Ersi Voskaridou, Birol Güvenç, Deborah Keefe, Kai Grosch, Michele L. Nassin, Jimmy Watson, Justin Yssel, Evgeniya Reshetnyak, Yvonne Adomakoh

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

    Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Cl... حسب Alice B. Gottlieb, Atul Deodhar, Iain B. McInnes, Xenofon Baraliakos, Kristian Reich, Stefan Schreiber, Weibin Bao, Kwaku Marfo, Hanno B. Richards, Luminita Pricop, Abhijit Shete, Vivek Trivedi, Deborah Keefe, C. Papavassilis, Piotr Jagiello, P. Papanastasiou, Philip J. Mease, Mark Lebwohl

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: